Management of anemia in patients with myelofibrosis

Author: Marijo Vodanović

Abstract: Ovaj članak je sponzorirala tvrtka Novartis Hrvatska d.o.o.

Key words:
anemia; JAK inhibitors; myelofibrosis; ruxolitinib; treatment

OGLASI